EHEdna C. Holman

Edna C. Holman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edna C. Holman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Byung Hak Ha

    Departments of aPharmacology

    2 shared publications
  • Ana Capatana

    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA

    1 shared publication
  • Antonella Bacchiocchi

    Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA

    1 shared publication
  • Craig M. Crews

    Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, USA

    1 shared publication
  • David F Stern

    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA

    1 shared publication
  • Deepak Narayan

    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA

    1 shared publication

Latest Publications

  • Open Access

    RAC1 P29S is a spontaneously activating cancer-associated GTPase

    by Matthew J. Davis, Byung Hak Ha, Edna C. Holman, Ruth Halaban, Joseph Schlessinger, Titus J. Boggon

    RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1 P29S ), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1 P29S protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1 F28L —a known spontaneously activated RAC1 mutant—and RAC1 P29S are self-activated in distinct fashions. Moreover, the mechanism of RAC1 P29S and RAC1 F28L activation differs from the common oncogenic mutations found in Ras-like GTPases that abrogate GTP hydrolysis. The melanoma RAC1 P29S gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity.


  • Open Access

    Microarray Analysis of microRNA Expression during Axolotl Limb Regeneration

    by Edna C. Holman, Leah J. Campbell, John Hines, Craig M. Crews

    Among vertebrates, salamanders stand out for their remarkable capacity to quickly regrow a myriad of tissues and organs after injury or amputation. The limb regeneration process in axolotls (Ambystoma mexicanum) has been well studied for decades at the cell-tissue level. While several developmental genes are known to be reactivated during this epimorphic process, less is known about the role of microRNAs in urodele amphibian limb regeneration. Given the compelling evidence that many microRNAs tightly regulate cell fate and morphogenetic processes through development and adulthood by modulating the expression (or re-expression) of developmental genes, we investigated the possibility that microRNA levels change during limb regeneration. Using two different microarray platforms to compare the axolotl microRNA expression between mid-bud limb regenerating blastemas and non-regenerating stump tissues, we found that miR-21 was overexpressed in mid-bud blastemas compared to stump tissue. Mature A. mexicanum (“Amex”) miR-21 was detected in axolotl RNA by Northern blot and differential expression of Amex-miR-21 in blastema versus stump was confirmed by quantitative RT-PCR. We identified the Amex Jagged1 as a putative target gene for miR-21 during salamander limb regeneration. We cloned the full length 3′UTR of Amex-Jag1, and our in vitro assays demonstrated that its single miR-21 target recognition site is functional and essential for the response of the Jagged1 gene to miR-21 levels. Our findings pave the road for advanced in vivo functional assays aimed to clarify how microRNAs such as miR-21, often linked to pathogenic cell growth, might be modulating the redeployment of developmental genes such as Jagged1 during regenerative processes.


  • Top Cited Papers
    Open Access

    Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

    by Michael Krauthammer, Yong Kong, Byung Hak Ha, Perry Evans, Antonella Bacchiocchi, Jamie P McCusker, Elaine Cheng, Matthew J Davis, Gerald Goh, Murim Choi, et al.

    Ruth Halaban and colleagues report exome sequences of 147 melanoma tumors. They identified a recurrent somatic activating alteration in the Rho GTPase RAC1 in sun-exposed melanomas. We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed melanomas had markedly more ultraviolet (UV)-like C>T somatic mutations compared to sun-shielded acral, mucosal and uveal melanomas. Among the newly identified cancer genes was PPP6C, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed melanomas, exclusively in tumors with mutations in BRAF or NRAS. Notably, we identified a recurrent UV-signature, an activating mutation in RAC1 in 9.2% of sun-exposed melanomas. This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of BRAF and NRAS, changes Pro29 to serine (RAC1P29S) in the highly conserved switch I domain. Crystal structures, and biochemical and functional studies of RAC1P29S showed that the alteration releases the conformational restraint conferred by the conserved proline, causes an increased binding of the protein to downstream effectors, and promotes melanocyte proliferation and migration. These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit.